Human papilloma virus: global research architecture assessed by density-equalizing mapping.

Dörthe Brüggmann, Luise Kayser, Jenny Jaque, Matthias Bundschuh, Doris Klingelhöfer, David A Groneberg
Author Information
  1. Dörthe Brüggmann: Department of Obstetrics and Gynecology, Keck School of Medicine of USC, Los Angeles, CA 90033, USA.
  2. Luise Kayser: Department of Female Health and Preventive Medicine, Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Frankfurt 60590, Germany.
  3. Jenny Jaque: Department of Obstetrics and Gynecology, Keck School of Medicine of USC, Los Angeles, CA 90033, USA.
  4. Matthias Bundschuh: Department of Female Health and Preventive Medicine, Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Frankfurt 60590, Germany.
  5. Doris Klingelhöfer: Department of Female Health and Preventive Medicine, Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Frankfurt 60590, Germany.
  6. David A Groneberg: Department of Female Health and Preventive Medicine, Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Frankfurt 60590, Germany.

Abstract

Human papilloma virus (HPV) infection is linked to cervical cancer, which represents the world's fourth most common cancer in women. So far, no detailed map of the worldwide HPV research architecture has been constructed. Hence, this study focuses on the chronological development and geographical distribution of the global HPV-specific publications and evaluates citation-based parameters as well as socioeconomic features of the publishing countries. In total, 29,330 HPV-related publications were identified. The US was the leading country with 12,270 publications. Only high-income-countries were found in the ranking of the fifteen most active countries with Germany, France, and Japan among the top five. Analysis of HPV research activity in relation to the economic strength demonstrated a lead position of Finland and Sweden with an average of 2248.78 and 1924.67 HPV-related publications per GDP in 1000 bn US-$, respectively. The most active upper-middle-income country was Mexico (416.78 HPV-related publications per GDP in 1000 bn US-$). India as lower-middle-income country reached a value of 279.78 HPV-related publications per GDP in 1000 bn US-$. Collaboration analysis pointed to the US as the center of the 4517 international HPV collaborations. The worldwide HPV-research landscape is dominated by North American and Western European countries. By contrast, a high prevalence of HPV-related cervical cancer is documented for low-income countries. Hence, HPV-related public health interventions and prevention research specifically tailored to these countries needs to be fostered by monetary support and international collaborations.

Keywords

References

  1. Int J Environ Res Public Health. 2014 May 28;11(6):5792-806 [PMID: 24879489]
  2. Lancet. 2011 Jan 15;377(9761):209-18 [PMID: 21216000]
  3. Vaccine. 2015 Mar 3;33(10):1284-90 [PMID: 25593103]
  4. N Engl J Med. 2007 May 10;356(19):1908-10 [PMID: 17494923]
  5. Proc Natl Acad Sci U S A. 2004 May 18;101(20):7499-504 [PMID: 15136719]
  6. Lancet Infect Dis. 2011 Aug;11(8):604-12 [PMID: 21489882]
  7. Parasit Vectors. 2010 Mar 04;3(1):14 [PMID: 20202187]
  8. Parasit Vectors. 2013 Nov 18;6:331 [PMID: 24245856]
  9. World Neurosurg. 2016 Jun;90:179-185 [PMID: 26898496]
  10. J Occup Med Toxicol. 2014 Jan 17;9(1):2 [PMID: 24438527]
  11. Diagn Cytopathol. 2005 Nov;33(5):344-51 [PMID: 16240403]
  12. Oncotarget. 2017 Jul 22;8(37):62274-62285 [PMID: 28977944]
  13. Lancet Glob Health. 2014 Jun;2(6):e323-33 [PMID: 25103301]
  14. Oncotarget. 2017 Apr 29;8(38):62914-62926 [PMID: 28968959]
  15. J Occup Med Toxicol. 2009 Jun 26;4:16 [PMID: 19555514]
  16. Oncotarget. 2017 May 16;8(20):33241-33251 [PMID: 28402260]
  17. Int J Cancer. 2006 Dec 1;119(11):2677-84 [PMID: 16991121]
  18. Int J Environ Res Public Health. 2009 Jun;6(6):1856-69 [PMID: 19578464]
  19. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16569-72 [PMID: 16275915]
  20. Oncotarget. 2017 May 18;8(31):50510-50520 [PMID: 28881579]
  21. Indian J Med Ethics. 2014 Jul-Sep;11(3):167-75 [PMID: 25101547]
  22. BMC Cancer. 2017 Nov 25;17(1):791 [PMID: 29178896]
  23. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:14-26 [PMID: 29037457]
  24. Oncotarget. 2017 Jul 18;8(38):63333-63344 [PMID: 28968993]
  25. EMBO Rep. 2009 Aug;10(8):800-3 [PMID: 19648952]
  26. J Virol. 1993 Dec;67(12):6929-36 [PMID: 8230414]
  27. Int J Environ Res Public Health. 2014 Sep 30;11(10):10202-14 [PMID: 25272079]
  28. Tuberculosis (Edinb). 2015 Jul;95(4):515-22 [PMID: 26032100]
  29. Oncotarget. 2017 May 16;8(31):51530-51541 [PMID: 28881665]
  30. Lancet Oncol. 2011 Oct;12(11):1023-31 [PMID: 21917519]
  31. BMC Infect Dis. 2013 Sep 30;13:454 [PMID: 24079616]
  32. Lancet Oncol. 2016 Jan;17(1):67-77 [PMID: 26652797]
  33. Sex Transm Dis. 2013 Mar;40(3):187-93 [PMID: 23403598]
  34. PLoS One. 2014 Sep 09;9(9):e106686 [PMID: 25203053]
  35. Vaccine. 2013 Nov 22;31 Suppl 8:I1-31 [PMID: 24229716]
  36. Lancet Oncol. 2015 May;16(5):e206-16 [PMID: 25943065]
  37. Diagn Cytopathol. 2012 Apr;40(4):355-66 [PMID: 21394935]
  38. Oncotarget. 2017 Jun 16;8(39):66352-66359 [PMID: 29029517]
  39. Vaccine. 2012 Nov 20;30 Suppl 4:xii [PMID: 23510773]
  40. Eur J Cancer. 2013 Oct;49(15):3262-73 [PMID: 23751569]
  41. Int J Cancer. 2018 Mar 1;142(5):949-958 [PMID: 29055031]
  42. Rheumatol Int. 2013 Nov;33(11):2743-50 [PMID: 23797780]
  43. PLoS One. 2014 Jun 26;9(6):e101114 [PMID: 24968002]
  44. J Infect Dis. 2010 Dec 15;202(12):1789-99 [PMID: 21067372]
  45. Oncotarget. 2017 May 23;8(21):34507-34515 [PMID: 28427144]
  46. PLoS One. 2014 Nov 19;9(11):e112026 [PMID: 25409503]
  47. Oncotarget. 2017 Mar 17;8(35):59831-59844 [PMID: 28938686]
  48. Oncotarget. 2017 Jun 30;8(58):97955-97964 [PMID: 29228665]
  49. J Viral Hepat. 2014 Nov;21(11):786-93 [PMID: 24205854]
  50. Vaccine. 2012 Nov 20;30 Suppl 5:F123-38 [PMID: 23199956]
  51. Oncotarget. 2017 May 30;8(22):36591-36602 [PMID: 28402266]
  52. Vaccine. 2012 Nov 20;30 Suppl 5:F12-23 [PMID: 23199955]
  53. JAMA Neurol. 2016 Jul 1;73(7):821-8 [PMID: 27214765]

Word Cloud

Created with Highcharts 10.0.0publicationsHPV-relatedHPVcountriesresearchpapillomacancercountry78perGDP1000bnUS-$HumanviruscervicalworldwidearchitectureHenceglobalUSactiveinternationalcollaborationsinfectionlinkedrepresentsworld'sfourthcommonwomenfardetailedmapconstructedstudyfocuseschronologicaldevelopmentgeographicaldistributionHPV-specificevaluatescitation-basedparameterswellsocioeconomicfeaturespublishingtotal29330identifiedleading12270high-income-countriesfoundrankingfifteenGermanyFranceJapanamongtopfiveAnalysisactivityrelationeconomicstrengthdemonstratedleadpositionFinlandSwedenaverage2248192467respectivelyupper-middle-incomeMexico416Indialower-middle-incomereachedvalue279Collaborationanalysispointedcenter4517HPV-researchlandscapedominatedNorthAmericanWesternEuropeancontrasthighprevalencedocumentedlow-incomepublichealthinterventionspreventionspecificallytailoredneedsfosteredmonetarysupportvirus:assesseddensity-equalizingmappingbibliometryhumanpublicationscientometry

Similar Articles

Cited By